Back to Search Start Over

Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties.

Authors :
Macdonald LE
Meagher KA
Franklin MC
Levenkova N
Hansen J
Badithe AT
Zhong M
Krueger P
Rafique A
Tu N
Shevchuk J
Wadhwa S
Ehrlich G
Bautista J
Grant C
Esau L
Poueymirou WT
Auerbach W
Morton L
Babb R
Chen G
Huang T
MacDonald D
Graham K
Gurer C
Voronina VA
McWhirter JR
Guo C
Yancopoulos GD
Murphy AJ
Source :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Jan 07; Vol. 117 (1), pp. 292-299. Date of Electronic Publication: 2019 Dec 26.
Publication Year :
2020

Abstract

We describe a Kappa-on-Heavy (KoH) mouse that produces a class of highly diverse, fully human, antibody-like agents. This mouse was made by replacing the germline variable sequences of both the Ig heavy-chain (IgH) and Ig kappa (IgK) loci with the human IgK germline variable sequences, producing antibody-like molecules with an antigen binding site made up of 2 kappa variable domains. These molecules, named KoH bodies, structurally mimic naturally existing Bence-Jones light-chain dimers in their variable domains and remain wild-type in their antibody constant domains. Unlike artificially diversified, nonimmunoglobulin alternative scaffolds (e.g., DARPins), KoH bodies consist of a configuration of normal Ig scaffolds that undergo natural diversification in B cells. Monoclonal KoH bodies have properties similar to those of conventional antibodies but exhibit an enhanced ability to bind small molecules such as the endogenous cardiotonic steroid marinobufagenin (MBG) and nicotine. A comparison of crystal structures of MBG bound to a KoH Fab versus a conventional Fab showed that the KoH body has a much deeper binding pocket, allowing MBG to be held 4 Å further down into the combining site between the 2 variable domains.<br />Competing Interests: Competing interest statement: G.D.Y. is a board member, employee, and shareholder of Regeneron Pharmaceuticals, Inc. Other authors are employees and shareholders of Regeneron Pharmaceuticals, Inc.

Details

Language :
English
ISSN :
1091-6490
Volume :
117
Issue :
1
Database :
MEDLINE
Journal :
Proceedings of the National Academy of Sciences of the United States of America
Publication Type :
Academic Journal
Accession number :
31879340
Full Text :
https://doi.org/10.1073/pnas.1901734117